Medical Science Liaison, Northwest

Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company developing innovative therapies for serious, rare skin and vascular conditions that currently have no FDA-approved therapies. With a pipeline of potentially first-in-disease assets and a clear path toward commercialization, Palvella offers a unique opportunity to join at a pivotal moment, helping bring meaningful therapies to patients with significant unmet medical needs.

At the core of Palvella's innovation is its patented QTORIN™ platform, which is designed to deliver therapies directly to affected tissue while minimizing systemic exposure. The platform supports the development of topical therapies that penetrate deep into the layers of the skin, reflecting Palvella's commitment to pairing scientific precision with real-world applicability for patients and clinicians.

Palvella's lead product candidate, QTORIN™ rapamycin, is being evaluated in clinical programs for microcystic lymphatic malformations (mLM) and cutaneous venous malformations (cVM). With a potential first commercial launch anticipated in early 2027 in mLM, this is a pivotal time to join Palvella, contribute to building its first commercial organization, and make a direct impact on patients, families, and the broader rare skin disease community.

The company is gearing up for what will be a transformational year in 2026 by adding a number of leaders to the management team in preparation for commercialization in early 2027.

You'll be joining a passionate, agile, and deeply experienced leadership team, including:

• Wes Kaupinen
  , Founder and Chief Executive Officer
• Jeff Martini , Ph.D., Chief Scientific Officer
• Matthew Korenberg
  , Chief Financial Officer
• Kathy Goin
  , Chief Operating Officer
• David Osborne , Ph.D., Chief Innovation Officer

You will report directly to Vimal Patel, Senior Vice President, Medical Affairs

The Medical Science Liaison (MSL) / Senior Medical Science Liaison (Senior MSL) is a field-based medical professional responsible for delivering high-quality, non-promotional scientific exchange and supporting clinical development activities across Palvella's rare disease portfolio.

The level (MSL vs. Senior MSL) will be determined based on experience, therapeutic expertise, and demonstrated field impact. Both roles are hands-on, externally focused, and deeply connected to the science.

The successful candidate is scientifically rigorous, externally credible, and deeply patient-focused. He or she will be motivated by advancing meaningful scientific dialogue in areas of high unmet need and by building trusted partnerships within the rare dermatology and vascular anomaly community. This individual will play a visible role in shaping Palvella's Medical Affairs presence during a pivotal stage of late-stage development and pre-commercial readiness.

• Deliver high-quality, balanced scientific exchange to dermatologists, vascular anomaly specialists, geneticists, and clinical investigators across assigned territory.
• Establish and maintain trusted, long-term relationships with key opinion leaders, academic centers, and vascular anomaly clinics.
• Communicate complex disease biology, mTOR pathway science, and QTORIN™ clinical data with clarity and scientific rigor.
• Support ongoing and planned clinical programs in microcystic lymphatic malformations, cutaneous venous malformations, and other rare dermatologic conditions.
• Generate and share actionable field insights to inform Medical Affairs strategy, clinical development planning, and future launch readiness.
• Partner cross-functionally with Clinical Development, Regulatory, and Commercial colleagues to ensure aligned…